ALK Mutations Conferring Differential Resistance to Structurally Diverse ALK Inhibitors

PURPOSE: EML4–ALK fusions define a subset of lung cancers that can be effectively treated with anaplastic lymphoma kinase (ALK) inhibitors. Unfortunately, the duration of response is heterogeneous and acquired resistance limits their ultimate efficacy. Thus, a better understanding of resistance mech...

Täydet tiedot

Tallennettuna:
Bibliografiset tiedot
Päätekijät: Heuckmann, Johannes M., Hölzel, Michael, Sos, Martin L., Heynck, Stefanie, Balke-Want, Hyatt, Koker, Mirjam, Peifer, Martin, Weiss, Jonathan, Lovly, Christine M., Grütter, Christian, Rauh, Daniel, Pao, William, Thomas, Roman K.
Aineistotyyppi: Artigo
Kieli:Inglês
Julkaistu: 2011
Aiheet:
Article
Linkit:https://ncbi.nlm.nih.gov/pmc/articles/PMC3382103/
https://ncbi.nlm.nih.gov/pubmed/21948233
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/1078-0432.CCR-11-1648
Tagit: Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!

Samankaltaisia teoksia